Breast cancer is the most commonly diagnosed cancer in women in the United States. The treatment for breast cancer occurs along a protracted time period and includes many different disease treatment modalities. These treatments carry with them a large number of side effects that negatively impact function in both the short-term and long-term. It is necessary for rehabilitation providers to interface with patients being treated for breast cancer throughout the continuum of care so that interval assessments can be conducted to identify emerging impairments and alleviate disability. In order to achieve this, the rehabilitation provider must have an understanding of the clinical measurement tools best suited for examination and assessment of breast cancer-related impairments and disability. This article aims to provide a comprehensive overview of the evidence supporting the use of various clinical measurement tools for the breast cancer population and highlights the implementation of rehabilitation examination and assessment along the continuum of disease treatment.
Introduction
Breast cancer treatment carries with it a high risk for treatment side effects that may negatively impact physical and psychological function.
1 Surgery, chemotherapy, radiation therapy, targeted agents, and hormonal therapies precipitate both immediate and late side effects associated with diminished function. Functional sequelae may inhibit return to work and performance of activities of daily living. 2 The burden of functional impact is significant, with over 60% of patients reporting at least one functional impairment during or after treatment for breast cancer. 3 Many common treatment side effects including; pain, lymphedema, fatigue, peripheral neuropathies and upper quadrant impairments, such as decreased shoulder range of motion and strength, faulty scapular mechanics, and reduced muscle length, are amenable to rehabilitation interventions. 1, 4 Rehabilitation interventions have additional efficacy in early identification and treatment of many of the aforementioned common breast cancer-related impairments. 5 Further, there is a strong evidence base to suggest that rehabilitation plays an integral role across the lifespan for the cancer survivor. 6 Providing interventions with demonstrable value is critically important in today's health care delivery system. Value is defined not only in cost outlays for an intervention, but in the efficacy realized for the cost of care rendered. Rehabilitation providers must demonstrate that the care delivered has positively impacted the functional outcome of a patient. A robust movement towards value-based outcomes measurement is evident in the regulatory realm among both private and public payers. While there is wide acceptance that breast cancer treatment side effects are amenable to rehabilitation intervention, the mandates being put forward in health care require providers not only to objectively demonstrate improvement over time but to show impact on improving function related to the intervention provided. This manuscript will provide the practicing rehabilitation provider with tools to enable evidence-based measurement of common breast cancer treatment-related impairments and outline the recommended outcomes tools for use in the breast cancer population.
Rehabilitation across the continuum of cancer care
Breast cancer treatment occurs over a protracted timeline with varying disease treatment interventions provided along that continuum; each introducing a host of potential side effects that may negatively impact function. Some side effects will dissipate after treatment is complete but some will remain and become chronic conditions. Still other side effects may not present until years after treatment has been completed. Many of the side effects that negatively impact function are amenable to rehabilitation intervention.
Some functional impairments can be detected early, in less severe stages, when rehabilitation examination techniques are employed proactively. Early surveillance and rehabilitation intervention may prevent some side effects and may greatly reduce the severity of others. 7 The current model of care delivery for the patient with breast cancer frequently fails to address the negative functional side effects of cancer treatment until the patient reaches a critical threshold of disability. At this point the impairment is typically more severe and may even be chronic in nature. The current evidence supports rehabilitation examination and ongoing assessment for early detection of impairments. Delaying rehabilitation frequently results in functional deficits. 8, 9 An ideal model of care proactively addresses physical function from the point of cancer diagnosis throughout the continuum of disease treatment, through survivorship and endures across the remaining lifespan. 10 ( Figure 1 
Choosing Clinical Measurement Tools
In order for the rehabilitation provider's clinical examination to identify potential effects that may be associated with breast cancer treatment, specific tests and measures should be performed. Tests and measures should be based on where the patient is along the disease treatment continuum, knowledge of the common side effects of treatment and impairments they may cause, and any presenting impairment in body function, structure or activity and participation limitation. Based on Table 3 Effectiveness (EDGE), specifically with the intent to identify measures that have strong psychometric properties for use in rehabilitation. 18 Useful outcome measures must demonstrate validity, reliability, be responsive to change, and preferably have identified minimal detectable change (MDC) and minimally clinically important difference (MCID)
values. The EDGE Taskforce of the Oncology Section of APTA has completed multiple systematic reviews of clinical measurement tools and classified these tools based on their level of supporting evidence using the EDGE rating system. Using this system, (Table 4) a rehabilitation provider can easily identify the clinical measurement tool with the strongest evidence for use in clinical practice with the breast cancer population. Tools rated 3 and 4 are recommended for clinical use. 
Breast Cancer Specific Objective Tests and Measures
Shoulder girdle muscle weakness is a commonly reported side effect from breast cancer treatment. 8, [19] [20] [21] [22] [23] A recent EDGE task force systematic review recommends using hand held dynamometry by means of a maximal voluntary isometric contraction to measure strength in a clinical setting. 24 Tools to assess strength are outlined in Table 5 .
Research suggests assessing scapula abduction and upward rotation, scapula depression and adduction, glenohumeral flexion, internal rotation, scaption and horizontal adduction strength as these were highly correlated with upper extremity functional loss in women diagnosed with breast cancer. 25 It is recommended that strength assessments be performed in a standardized manner such as published in Kendall or Hislop and Montgomery. 26, 27 Several studies have reported restricted shoulder motion in women who have received treatment for breast cancer. 8, 20, [28] [29] [30] [31] Table 5 reflects the recommended tools for measuring ROM by the EDGE task force. Passive ROM using goniometry has superior psychometric properties over active ROM. 32 A recent study recommends assessing bilateral shoulder flexion, 90°ER and extension as results showed that women treated for breast cancer demonstrated significant limitations in these motions six months after breast surgery on the involved side when compared to matched healthy controls. 20 It is advised that ROM assessments be performed in a standardized manner. 33 Limb volume is essential to measure as breast cancer-related lymphedema is a concern for many women diagnosed with breast cancer. [34] [35] [36] The incidence of breast cancer-related lymphedema varies from 6% to 65% depending on the assessment tool and length of follow-up. [37] [38] [39] Circumferential measurement, water displacement and bioelectrical impedance spectroscopy are highly recommended methods for assessment of limb volume as noted by the EDGE task force systematic review and highlighted in Table 6 . 40 The simplest of these three measures for clinical use is circumferential measurement. It is recommended that the individual be seated with their forearm pronated, and the upper extremity placed on a treatment table or measurement board in approximately 90° of forward flexion or abduction. 41, 42 Using 4cm increments proximal and distal to the olecranon is reliable. 42 In order to convert circumferential measurement to a volumetric measure, the truncated Frustum formula is recommended. 40, 43 Pain is one of the most commonly reported impairments after breast cancer treatment affecting anywhere from 16% to 73% of women treated for breast cancer. 44, 45 When assessing pain in women with breast cancer, it is important to determine whether a uni-dimensional or multidimensional tool is more appropriate. 46 Administering the visual analog scale, numeric rating scale or pressure pain threshold is recommended if using a uni-dimensional tool is desired. When a multidimensional tool is needed, the McGill Pain Questionnaire, McGill Pain Questionnaire -Short Form, Pain Disability index, Brief
Pain Inventory, or Brief Pain Inventory -Short Form could be utilized. 46 Table 7 highlights the tools evaluated by the EDGE task force for both uni-dimensional and multi-dimensional pain scales.
Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of chemotherapy and biotherapy drugs often used to treat breast cancer. 47 CIPN can lead to emotion distress, a decrease in functional ability, social role impairment and physical distress from neuropathic pain. 47 
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Breast Cancer-Specific Patient Self-Reported Measures
As the population of women living after breast cancer continues to increase, overall quality of life has become an essential focus during and after initial treatment.
There are a number of scales that assess breast cancer-specific quality of life. The recommended tools for use in this population are outlined in Table 8 .
The ability to use the upper extremity is essential for activities of daily living as well as for many occupational demands. Many women treated for breast cancer exhibit a loss of shoulder function in the sub-acute stages after their primary treatment. 20, 58, 59 There are a number of self-reported scales that capture the impact of pain, limited upper extremity mobility and strength on overall function as outlined in Table 9 .
Cancer related fatigue is a disabling symptom reported by women diagnosed with breast cancer to significantly impact quality of life. [60] [61] [62] Similar to pain assessment, it is important to determine whether a uni-dimensional or multidimensional tool is better suited to assess fatigue in a particular patient population. A recent systematic review suggests using the Brief Fatigue Inventory when planning to administer a unidimensional tool or the Multidimensional Fatigue Symptom Inventory -Short Form when wanting to implement a multidimensional tool. 63 Table 10 outlines the uni-dimensional and multi-dimensional assessment tools evaluated by the EDGE task force to assess fatigue. 
